Date: 2016-03-21
Type of information: Nomination
Compound:
Company: GlycoMimetics (USA - Md)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: • On March 21, 2016, GlycoMimetics announced the appointment of Daniel Junius to its Board of Directors. Mr. Junius is President and Chief Executive Officer and a member of the board of directors of ImmunoGen, an industry leader in the field of antibody drug conjugates (ADCs). He also serves on the Board of Directors of IDEXX Laboratories, a leading provider of diagnostic and information technology-based products and services for pet healthcare innovation. Daniel Junius was promoted to President and Chief Operating Officer of ImmunoGen in July 2008 and became President and Chief Executive Officer of the company in 2009. He joined ImmunoGen as Chief Financial Officer (CFO) and Senior Vice President, Finance in May 2005 and was promoted to Executive Vice President, Finance and CFO in July 2006.
Financial terms:
Latest news:
